Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conbercept versus aflibercept in treatment-naive neovascular age-related macular degeneration
NL-OMON48627Phase 3Active, not recruiting
- Sponsor
- Chengdu Kanghong Biotechnology Co., Ltd.
- Start
- Feb 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of conbercept and aflibercept in exudative macular degeneration (3 arms), sponsored by Chengdu Kanghong Biotechnology Co., Ltd. Primary endpoint: Mean change from baseline in ETDRS BCVA letter score at Week 36. Started Feb 2019; status: active, not recruiting.
02
Drugs
conberceptaflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NL-OMON48627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48627.